Cat. No.: HY-12993

RSV604

(Synonyms: A-60444)

2 Cited Publications

Customer Review

Based on 2 publication(s) in Google Scholar

RSV604 (A-60444) is an inhibitor of respiratory syncytial virus (RSV) replication. RSV604 targets the nucleocapsid protein, with a K_d of 1.6 μM. RSV604 displays submicromolar activity against numerous clinical isolates of both the A and B subtypes of RSV (average EC₅₀s=0.8 μM).

For research use only. We do not sell to patients.

Purity: 99.55%
CAS No.: 676128-63-5
Formula: C₂₂H₁₇FN₄O₂
Molecular Weight:388.39

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

RSV604 Chemical Structure

CAS No.: 676128-63-5

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- Clinical Trial
Chemical Information
Publications (2)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target

Kd: 1.6 μM (nucleocapsid protein)^[2]

Cellular Effect

Cell Line	Type	Value	Description	References
HEp-2	CC₅₀	>50 μM Compound: RSV604	Cytotoxicity against RSV RSS infected human Hep2 cells after 6 days by XTT assay Cytotoxicity against RSV RSS infected human Hep2 cells after 6 days by XTT assay	[PMID: 17576833]
HEp-2	EC₅₀	>20 μM Compound: RSV604	Antiviral activity against RSV RSS with N protein I129L plus L139I mutant mutation in human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against RSV RSS with N protein I129L plus L139I mutant mutation in human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	>50 μM Compound: RSV604	Antiviral activity against human Metapneumovirus infected human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against human Metapneumovirus infected human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	>50 μM Compound: RSV604	Antiviral activity against Parainfluenza virus type 1 infected human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against Parainfluenza virus type 1 infected human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	>50 μM Compound: RSV604	Antiviral activity against Parainfluenza virus type 3 infected human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against Parainfluenza virus type 3 infected human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	>50 μM Compound: RSV604	Antiviral activity against Pneumonia virus of mice 15 infected human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against Pneumonia virus of mice 15 infected human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	0.3 μM Compound: RSV604	Antiviral activity against bovine RSV snook infected human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against bovine RSV snook infected human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	0.5 μM Compound: RSV604	Antiviral activity against RSV A2 infected human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against RSV A2 infected human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	0.6 μM Compound: RSV604	Antiviral activity against DMSO-passaged wild type RSV RSS infected human Hep2 cells by plaque reduction assay Antiviral activity against DMSO-passaged wild type RSV RSS infected human Hep2 cells by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	0.6 μM Compound: RSV604	Antiviral activity against RSV B infected human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against RSV B infected human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	0.8 μM Compound: RSV604	Antiviral activity against RSV A isolates infected human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against RSV A isolates infected human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	0.8 μM Compound: RSV604	Antiviral activity against RSV B isolates infected human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against RSV B isolates infected human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	0.8 μM Compound: RSV604	Antiviral activity against RSV Long infected human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against RSV Long infected human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	0.86 μM Compound: RSV604	Antiviral activity against RSV RSS infected human Hep2 cells assessed as inhibition of virus-induced cell death after 6 days by XTT assay Antiviral activity against RSV RSS infected human Hep2 cells assessed as inhibition of virus-induced cell death after 6 days by XTT assay	[PMID: 17576833]
HEp-2	EC₅₀	0.9 μM Compound: RSV604	Antiviral activity against RSV RSS infected human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against RSV RSS infected human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	1.14 μM Compound: RSV604	Antiviral activity against RSV RSS M2 mutant infected human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against RSV RSS M2 mutant infected human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	1.4 μM Compound: RSV604	Antiviral activity against 0.02 MOI RSV RSS infected human Hep2 cells assessed as inhibition of virus-induced cell death after 6 days by XTT assay Antiviral activity against 0.02 MOI RSV RSS infected human Hep2 cells assessed as inhibition of virus-induced cell death after 6 days by XTT assay	[PMID: 17576833]
HEp-2	EC₅₀	1.7 μM Compound: RSV604	Antiviral activity against RSV RSS infected human Hep2 cells assessed as reduction of viral antigen synthesis after 3 days by ELISA Antiviral activity against RSV RSS infected human Hep2 cells assessed as reduction of viral antigen synthesis after 3 days by ELISA	[PMID: 17576833]
HEp-2	EC₅₀	2.55 μM Compound: RSV604	Antiviral activity against 1.5 MOI RSV RSS infected human Hep2 cells assessed as inhibition of virus-induced cell death after 6 days by XTT assay Antiviral activity against 1.5 MOI RSV RSS infected human Hep2 cells assessed as inhibition of virus-induced cell death after 6 days by XTT assay	[PMID: 17576833]
HEp-2	EC₅₀	2.7 μM Compound: RSV604	Antiviral activity against plaque picked A-33903-resistant RSV RSS from passage 2 in human Hep2 cells by plaque reduction assay Antiviral activity against plaque picked A-33903-resistant RSV RSS from passage 2 in human Hep2 cells by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	30.4 μM Compound: RSV604	Antiviral activity against plaque picked RSV604-resistant RSV RSS from passage 2 in human Hep2 cells by plaque reduction assay Antiviral activity against plaque picked RSV604-resistant RSV RSS from passage 2 in human Hep2 cells by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	4.78 μM Compound: RSV604	Antiviral activity against RSV RSS with N protein N105D mutation in human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against RSV RSS with N protein N105D mutation in human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	6.03 μM Compound: RSV604	Antiviral activity against RSV RSS with N protein I120L mutation in human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against RSV RSS with N protein I120L mutation in human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	6.7 μM Compound: RSV604	Antiviral activity against RSV RSS with N protein L139I mutation in human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against RSV RSS with N protein L139I mutation in human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	IC₅₀	0.7 μM Compound: 17b, RSV-604	Antiviral activity against RSV RSS in Hep2 cells by plaque assay Antiviral activity against RSV RSS in Hep2 cells by plaque assay	[PMID: 17341059]
HEp-2	IC₅₀	0.9 μM Compound: 17b, RSV-604	Antiviral activity against RSV RSS in Hep2 cells by XTT assay Antiviral activity against RSV RSS in Hep2 cells by XTT assay	[PMID: 17341059]
HEp-2	IC₅₀	1.4 μM Compound: 17b, RSV-604	Antiviral activity against RSV RSS in Hep2 cells by ELISA Antiviral activity against RSV RSS in Hep2 cells by ELISA	[PMID: 17341059]

In Vitro

RSV604 (5 days) inhibits the growth of four laboratory strains of RSV (RSS, Long, A2 and B), with EC₅₀s ranging from 0.5 to 0.9 μM in plaque reduction assay^[1].
RSV604 (6 days) inhibits RSV-induced HEp-2 cell death, with an EC₅₀ of 0.86 μM^[1].
RSV604 (3 days) reduces viral antigen synthesis in RSV-infected HEp-2 cells, with an EC₅₀ of 1.7 μM^[1].
RSV604 (1-20 μM; 7 days) dose-dependently inhibits RSV infection in human airway epithelial (HAE) cells, with no gross cytotoxicity, leakage of basolateral fluid to the apical surface, or alteration of cilium beat frequency^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 676128-63-5
Appearance Solid
Molecular Weight 388.39
Formula C₂₂H₁₇FN₄O₂
Color White to off-white
SMILES

O=C1[C@@H](NC(NC2=C(F)C=CC=C2)=O)N=C(C3=CC=CC=C3)C4=CC=CC=C4N1
Synonyms

A-60444
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (2)

All

Sort by:

Journal Impact Factor

J Enzyme Inhib Med Chem

The mechanism and pharmacodynamics of 2-((1H-indol-3-yl)thio/sulfinyl)-N-pheny acetamide derivative as a novel inhibitor against human respiratory syncytial virus. [Abstract]

2022 Dec;37(1):2598-2604. PMID: 36131622
J Org Chem

Protecting-Group-Mediated Diastereoselective Synthesis of C4'-Methylated Uridine Analogs and Their Activity against the Human Respiratory Syncytial Virus. [Abstract]

2020 Mar 20;85(6):4267-4278. PMID: 32036652

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (257.47 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5747 mL

12.8737 mL

25.7473 mL

5 mM

0.5149 mL

2.5747 mL

5.1495 mL

10 mM

0.2575 mL

1.2874 mL

2.5747 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.44 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.44 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.44 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Chapman J, et al. RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob Agents Chemother. 2007 Sep;51(9):3346-53. [Content Brief]

[2]. Challa S, et al. Mechanism of action for respiratory syncytial virus inhibitor RSV604. Antimicrob Agents Chemother. 2015 Feb;59(2):1080-7. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5747 mL	12.8737 mL	25.7473 mL	64.3683 mL
	5 mM	0.5149 mL	2.5747 mL	5.1495 mL	12.8737 mL
	10 mM	0.2575 mL	1.2874 mL	2.5747 mL	6.4368 mL
	15 mM	0.1716 mL	0.8582 mL	1.7165 mL	4.2912 mL
	20 mM	0.1287 mL	0.6437 mL	1.2874 mL	3.2184 mL
	25 mM	0.1030 mL	0.5149 mL	1.0299 mL	2.5747 mL
	30 mM	0.0858 mL	0.4291 mL	0.8582 mL	2.1456 mL
	40 mM	0.0644 mL	0.3218 mL	0.6437 mL	1.6092 mL
	50 mM	0.0515 mL	0.2575 mL	0.5149 mL	1.2874 mL
	60 mM	0.0429 mL	0.2146 mL	0.4291 mL	1.0728 mL
	80 mM	0.0322 mL	0.1609 mL	0.3218 mL	0.8046 mL
	100 mM	0.0257 mL	0.1287 mL	0.2575 mL	0.6437 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

RSV604

Anti-Infection Compound Library

Clinical Compound Library

Antiviral Compound Library

Drug Repurposing Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) RSV604

Biological Activity

Chemical Information

Publications (2)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

RSV604

Anti-Infection Compound Library

Clinical Compound Library

Antiviral Compound Library

Drug Repurposing Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) RSV604

Biological Activity

Chemical Information

Publications (2)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

RSV604 Related Classifications

Cat. No.: HY-12993